论文部分内容阅读
目的:比较原发性胃、肠弥漫性大B细胞淋巴瘤(PG-DLBCL,PI-DLBCL)的临床特性、免疫学分型。方法:收集26例PG-DLBCL及19例PI-DLBCL,用Hans、Choi和Tally三种免疫学分型法则进行免疫学分型。结果:临床分期上81.3%(13/16)的PG-DLBCL为I/II期,而PI-DLBCL的I/II期者仅占46.7%(7/15)。PG-DLBCL的临床分期倾向低于PI-DLBCL,尽管差异未达统计学意义(P=0.066)。三种法则分型结果均显示PG-DLBCL的GCB亚型比率较高,与non-GCB(或ABC)亚型比率接近,而PI-DLBCL则以non-GCB(或ABC)亚型为主,GCB亚型比率较低。尤其是在使用Tally法则进行免疫学分型时,PG-DLBCL的GCB亚型数显著高于PI-DLBCL的GCB亚型数(P=0.03)。结论:PG-DLBCL具有与PI-DLBCL不同的临床生物学特性,与PI-DLBCL相比,PG-DLBCL的临床分期较低,多为I-II期,GCB亚型比率较高。
Objective: To compare the clinical features and immunological typing of primary gastric and intestinal diffuse large B cell lymphoma (PG-DLBCL, PI-DLBCL). Methods: 26 cases of PG-DLBCL and 19 cases of PI-DLBCL were collected and immunotyped by immunological typing of Hans, Choi and Tally. Results: 81.3% (13/16) of PG-DLBCL were stage I / II in clinical stage, while only 46.7% (7/15) in stage I / II of PI-DLBCL. The clinical stage of PG-DLBCL tended to be lower than PI-DLBCL, although the difference was not statistically significant (P = 0.066). The three rule typing results showed that the ratio of GCB subtype of PG-DLBCL was higher than that of non-GCB (or ABC) subtype, while the non-GCB (or ABC) subtype of PI-DLBCL was predominant in PG- GCB subtype is lower. Especially when using Tally’s rule for immunological typing, the GCB subtype of PG-DLBCL was significantly higher than that of PI-DLBCL (P = 0.03). Conclusion: PG-DLBCL has different clinical biological characteristics compared with PI-DLBCL. Compared with PI-DLBCL, PG-DLBCL has lower clinical stage, mostly I-II stage, and higher GCB subtypes.